Lexeo Therapeutics to Participate in Upcoming Investor Conferences
/EIN News/ -- NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that company management will participate in fireside chats at the following investor conferences:
The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 at 9:00 AM ET
RBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14, 2024 at 11:00 AM ET
Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:40 AM PT
The events will be webcast live under the News & Events tab in the Investors section of our website. Replays of the webcasts will be available on the website following the presentations.
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer’s disease programs.
Media Response:
Janine Bogris
(201) 245-6838
janine.bogris@inizioevoke.com
Investor Response:
Stephen Jasper
(858) 525-2047
stephen@gilmartinir.com
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
